Histone Deacetylase Inhibitors (HDIs): Pharmacology, Uses and Health Effects

$130.00

Beverly D. Carson (Editor)

Series: Recent Advances in Hematology Research
BISAC: MED038000

Histone deacetylase inhibitors (HDIs) are good anti-cancer targets. Histone acetyltransferases (HATs) and HDIs play opposite roles in the regulation of gene expression via an epigenetic mechanism. HATs catalyze the acetylation of lysine residues in histone tails, facilitating and sustaining gene transcription. HDIs remove the acetyl moieties from the epsilon-amine of lysine residues of histone tails, leading to a more condensed form of chromatin and preventing gene transcription. This book focuses on the use of HDIs for the treatment of lymphoid malignancies; myeloid malignancies; and breast cancer. (Imprint: Nova Biomedical)

Clear

Description

Table of Contents

Preface

Classification and Function of Histone Deacetylase Inhibitors
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Histone Deacetylase Inhibitors in the Treatment of Lymphoid Malignancies
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Histone Deacetylase Inhibitors in the Treatment of Myeloid Malignancies
(Ota Fuchs, Institute of Hematology and Blood Transfusion, Prague, Czech Republic)

Histone Deacetylase Inhibitors for Breast Cancer: Driving out of Stemness
(Marion A. Salvador, Daniel Birnbaum, Emmanuelle Charafe-Jauffret and Christophe Ginestier, Inserm, CRCM, Laboratoire d’Oncologie Moléculaire, Marseille, France, and others)

Index

Additional information

Binding

,